Dr. Yorio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6204 Balcones Dr
Austin, TX 78731Phone+1 512-427-9400Fax+1 512-342-2723
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2008 - 2011
- University of Texas Southwestern Medical SchoolClass of 2008
Certifications & Licensure
- TX State Medical License 2010 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients.Jeffrey Thomas Yorio, Aviva G Asnis-Alibozek, Vijay Kasturi, Thomas E Hutson
BMC Health Services Research. 2024-10-25 - 2 citationsA Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B Goodman Jr
European Urology Oncology. 2024-08-01 - 2 citationsSafety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, ...Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina
BMJ Open. 2022-09-14
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: